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  A 
century ago Paul Ehrlich 
proposed that immune 
reactivity against self, which he 
called “horror autotoxicus” and which 
is now called autoimmunity, would 
be incompatible with life because of 
potentially devastating consequences 
for the host. But Ehrlich was proven 
wrong after the demonstration of 
autoantibodies and the emergence of a 
theoretical basis for autoreactivity [1]. 
Conceptually, autoimmunity is viewed 
as a defect of either B or T lymphocyte 
selection, with aberrant lymphocytic 
responses to autoantigens [2]. In 
recent years, an improved genetic 
understanding of both common and 
rare diseases, collectively associated 
with mutations reﬂ  ecting immune 
system perturbations—ranging from 
the thymus, to B and T cells, to T 
regulatory cells—has vindicated the 
autoimmunity paradigm [3] (Table 1).
    Problems with the Concept 
of Autoimmunity
    Nevertheless, there are several 
difﬁ  culties with the autoimmunity 
concept when considering self-
directed tissue inﬂ  ammation. These 
difﬁ  culties include a lack of major 
histocompatibility complex (MHC) 
and autoantibody associations in 
many diseases, tentatively labelled as 
autoimmune. A gradual appreciation 
of these difﬁ  culties has led to revised 
deﬁ  nitions of autoimmunity, but this 
approach fails to deﬁ  ne when self-
directed tissue inﬂ  ammation is not 
autoimmune in origin [4]. 
    And there is yet another weakness 
in the concept of autoimmunity: the 
idea that the immune system functions 
by making a distinction between self 
and nonself has come under scrutiny 
for failing to explain a number of 
ﬁ  ndings. For example, “Why do 
we fail to reject tumors, even when 
many clearly express new or mutated 
proteins? Why do most of us harbor 
autoreactive lymphocytes without any 
sign of autoimmune disease, while a 
few individuals succumb?” [5]. 
    To answer these questions, Polly 
Matzinger proposed the “danger 
signal theory,” which proposes 
that the immune system is not so 
much concerned with self/nonself 
discrimination but with mounting 
responses to danger signals, including 
exogenous pathogenic bacteria and 
endogenous damaged tissues [5]. 
However, the danger model does not 
account adequately for the exquisite 
speciﬁ  city of the adaptive immune 
responses in autoimmune diseases. 
This article draws on recent advances 
from genetic and molecular studies 
and improved clinical insights into 
disease in order to propose a uniﬁ  ed 
classiﬁ  cation and theoretical framework 
for all immunological diseases. 
    Key Studies That Deﬁ  ned 
Autoinﬂ  ammation as the Opposite 
of Autoimmunity 
    The recent elucidation of mechanisms 
underlying self-directed tissue 
inﬂ  ammation independent of B or T 
cell abnormalities could potentially 
transform our understanding of 
immunological diseases (Table 1). 
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  Box 1. Deﬁ  nitions of 
Autoimmunity and 
Autoinﬂ  ammation 
   Generic  Deﬁ  nition of Autoimmunity
   Self-directed  inﬂ  ammation, whereby 
aberrant dendritic cell, B and T cell, 
responses in primary and secondary 
lymphoid organs lead to breaking of 
tolerance, with development of immune 
reactivity towards native antigens. The 
adaptive immune response plays the 
predominant role in the eventual clinical 
expression of disease. Organ-speciﬁ  c 
autoantibodies may predate clinical 
disease expression by years and manifest 
before target organ damage is discernible.
   Proposal  for  a  Deﬁ  nition 
of Autoinﬂ  ammation
   Self-directed  inﬂ  ammation, whereby local 
factors at sites predisposed to disease 
lead to activation of innate immune cells, 
including macrophages and neutrophils, 
with resultant target tissue damage. 
For example, disturbed homeostasis 
of canonical cytokine cascades (as in 
the periodic fevers), aberrant bacterial 
sensing (as in Crohn disease), and tissue 
microdamage predispose one to site-
speciﬁ  c inﬂ  ammation that is independent 
of adaptive immune responses. PLoS Medicine  |  www.plosmedicine.org 1243
Paradoxically, the background to these 
discoveries is over a century old, with 
Eli Metchnikoff’s seminal observations 
that described how phagocytic 
cells, rather than serum factors (or 
antibodies), were responsible for 
inﬂ  ammatory tissue reactions against 
foreign antigens. 
    Fifty years later came recognition 
of the clinical entities subsequently 
known as hereditary periodic fevers 
(HPFs) [6], which are now known 
to include tumour necrosis factor 
(TNF) receptor–associated periodic 
fever syndrome (TRAPS) [7], 
familial Mediterranean fever (FMF), 
hyperimmunoglobulinaemia D with 
periodic fever syndrome (HIDS), 
and several others (Table 1). The key 
breakthrough came in Daniel Kastner’s 
laboratory by using a candidate gene 
approach in families with a rare 
autosomal dominant HPF termed 
familial Hibernian fever, initially in 
the prototypic familial Hibernian 
fever family from Nottingham, as well 
as in a series of families drawn from 
both Europe and the United States. 
Mutations in the TNF1 receptor, 
which is widely distributed on both 
immune and nonimmune cells, were 
shown in six families. This led the 
authors to propose the term TNF 
receptor–associated periodic syndrome 
(TRAPS) and to coin the term 
autoinﬂ  ammation, in recognition of an 
immunopathogenesis that was distinct 
from autoimmunity [7]. 
    It now appears that TRAPS and other 
monogenic periodic fever disorders 
share a common thread. They all show 
disturbances in pathways associated 
with innate immune cell function, 
encompassing abnormal signalling in 
key cytokine pathways that include TNF 
and interleukin-1 (IL-1β) (via adaptor 
molecules collectively termed the 
inﬂ  ammasome [8]), as well as through 
mutations in proteins associated with 
bacterial sensing [9,10] (Table 2). 
    Jérôme Galon and colleagues 
proposed that polygenic diseases 
sharing clinical features in common 
with the HPFs and lacking autoantibody 
or MHC associations could, by default, 
be termed autoinﬂ  ammatory in 
nature [10]. Indeed, the recognition 
of innate immune-related factors at 
target sites of disease, rather than 
adaptive immunity, has led to the 
idea of classifying some conditions 
(such as Crohn disease and Behçet 
syndrome) as being autoinﬂ  ammatory 
[10,11]. However, this classiﬁ  cation 
remains highly controversial, given 
that evidence for autoantibodies and 
autoimmune-like reactions is also a 
feature of these diseases [12]. Also, the 
logical consequence of this approach 
is a resulting two-tiered classiﬁ  cation 
for some, but not all, immunological 
diseases. 
  Autoimmunity  versus 
Autoinﬂ  ammation
    The issues pertaining to 
immunological disease classiﬁ  cation 
are compounded by the absence 
  Table 1.   Genetic and Cellular Basis for Autoimmunity and Autoinﬂ  ammation   
Type of Disease Inﬂ  ammatory Disorder Gene/Protein Cellular Distribution/Function
Monogenic autoimmune disease APS-1  AIRE /AIRE Thymic epithelium/negative T cell selection
IPEX  FOXP3 /FOXP3 Regulatory T cells/immunomodulation
ALPS  FAS /FAS Widespread/key role in lymphocyte apoptosis
Polygenic disease with a prominent autoimmune 
component
SLE, TID, AITD  CTLA-4 /CTLA-4 Regulation of T lymphocytes activation
RA, SLE, T1D  PTPN22 /PTPN22 Regulation of T lymphocytes activation
Many disorders MHC associations Multiple T cell functions, including B cell help
Monogenic autoinﬂ  ammatory disease FMF  MEFV /pyrin Neutrophils, early monocyte lineage, stromal 
cells/regulation of inﬂ  ammatory response
HIDS  MVK /mevalonate kinase Widespread/cholesterol biosynthesis, prenylation
TRAPS  TNFRSF1A / TNFR1 Widespread/TNF receptor
FCAS  CIAS1/NALP3 // cryopyrin/NALP3 Monocytes, stromal cell lineage/regulation of 
inﬂ  ammation
MWS  CIAS1/NALP3 // cryopyrin/NALP3
CINCA  CIAS1/NALP3 // cryopyrin/NALP3
PAPA  PSTPIP1 /PSTPIP1 Neutrophils and monocytes/regulation of 
inﬂ  ammation
CRMO  LPIN2  (in humans)/undeﬁ  ned Widespread distribution/undeﬁ  ned
 PSTPIP2  (in mouse)/MAYP Macrophage/regulation of inﬂ  ammatory 
responses
Blau syndrome  NOD2 /NOD2 Macrophages, Paneth cells/bacterial sensing
Polygenic disease with a prominent 
autoinﬂ  ammatory component
Crohn disease  NOD2 /NOD2 Macrophages, Paneth cells/bacterial sensing
 DOI:  10.1371/journal.pmed.0030297.t001
    This table lists some genes known to be associated with self-directed inﬂ  ammation, as well as their distribution and putative functions, where known. All autoimmune disease–associated 
mutations described so far have been in proteins associated with adaptive immune responses. These proteins are expressed in the thymus or in B and T cells and T regulatory cells. MHC 
polymorphisms have also been reported in the diseases commonly regarded as autoimmune in nature. Conversely, all mutations described thus far in the autoinﬂ  ammatory diseases are 
in proteins that do not speciﬁ  cally play a role in adaptive immunity but are expressed on innate immune cells or with a more widespread nonimmune cell distribution. Collectively, these 
mutations are typically associated with episodic bouts of uncontrolled inﬂ  ammation.
    AIRE, autoimmune regulator protein; AITD, autoimmune thyroid disease; ALPS, autoimmune lymphoproliferative syndrome; APS-1, autoimmune polyendocrine syndrome-1; CIAS, cold-
induced autoinﬂ  ammatory syndrome 1; TNFRSF, TNF super family receptor; CINCA, chronic infantile neurologic, cutaneous and articular syndrome; CMRO, chronic multifocal recurrent 
osteomyelitis; CTLA4, cytotoxic T-lymphocyte antigen 4; FCAS, familial cold autoinﬂ  ammatory syndrome; FMF, familial Mediterranean fever; HIDS, hyper-IgD syndrome; IPEX, immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked; FOXP3, forkhead box P3; MAYP, macrophage actin-associated tyrosine phosphorylated protein; MEFV, Mediterranean fever 
protein; MWS, Muckle-Wells syndrome; NALP, NAcht, LRR, and PYD domains; PSTPIP1, proline serine threonine phosphatase-interacting protein; NOD, nucleotide-binding oligomerization 
domain; PAPA, pyogenic sterile arthritis, pyoderma gangrenosum, and acne; PTPN22, protein tyrosine phosphatase 22 (PSTPIP1 and PSTPIP2 are thought to be closely related proteins. 
The CMRO phenotype in humans is associated with LPIN2 mutations and the CMRO phenotype in rodents is associated with the   PSTPIP2  gene. Formal identiﬁ  cation of protein encoded by 
LPIN2 in humans is awaited); SLE, systemic lupus erythematosus; T1D, type 1 diabetes; TLR4, Toll receptor-4; TRAPS, TNF-receptor-associated periodic syndrome. 
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of a precise deﬁ  nition of what 
constitutes autoinﬂ  ammation in the 
common polygenic diseases. This is 
in contrast to polygenic autoimmune 
disease, where a broad consensus 
on a generic deﬁ  nition exists (Box 
1). Autoinﬂ  ammation may simply 
be deﬁ  ned as self-directed tissue 
inﬂ  ammation, where local factors 
at disease-prone sites determine 
activation of the innate immune 
system. Such a deﬁ  nition would 
encompass autoinﬂ  ammatory 
mechanisms across the spectrum 
of immunological disease. Indeed, 
several tissue-speciﬁ  c factors that could 
contribute to inﬂ  ammation have been 
recognised (Box S1). 
    Based on this deﬁ  nition, many 
common diseases with strong 
inﬂ  ammatory components could 
be classed as predominantly 
autoinﬂ  ammatory in nature, although 
most of these conditions also have 
evidence for autoimmunity in the 
clinical setting (Figure 1). Importantly, 
this deﬁ  nition of autoinﬂ  ammation 
allows for the establishment of 
speciﬁ  c boundaries for what 
constitutes self-directed inﬂ  ammation. 
Furthermore, all immunological 
disease can then be conceptualised 
as being purely autoinﬂ  ammatory or 
autoimmune, or being a combination 
of autoinﬂ  ammatory–autoimmune 
mechanisms that variably interact in 
the phenotypic expression of disease 
(Figure 1). Thus, the boundaries for 
autoimmunity are set by mutations 
associated with the monogenic 
autoimmune diseases, which show 
an increased propensity towards 
adaptive immune responses and which 
are recognisable by the presence of 
autoantibodies. On the other hand, 
the boundaries of autoinﬂ  ammation 
are deﬁ  ned by mutations in cells or 
molecules involved in innate immune 
responses at disease-prone sites, where 
disease expression cannot be explained 
by autoimmune mechanisms.
    For example, Crohn disease is the 
ﬁ  rst polygenic disease with a genetically 
deﬁ  ned autoinﬂ  ammatory component, 
which was deﬁ  ned simultaneously 
by two groups who showed that the 
disease-associated mutation occurred 
in a protein involved in innate immune 
responses [13,14]. Speciﬁ  cally, the 
NOD2-associated mutations are 
thought to be linked to aberrant 
intracellular innate immune responses 
to bacterial peptidoglycan [15]. In 
addition to its expression on cells of the 
monocyte lineage, the NOD2 protein 
is also expressed on gut epithelial cells. 
Moreover, carriage of two copies of the 
  NOD2   mutation is associated with site-
speciﬁ  c involvement of the ileum and 
severe stricturing disease [16].
    Gout is the ﬁ  rst common polygenic 
condition with a molecular basis that 
is reminiscent of the monogenic 
autoinﬂ  ammatory diseases. The 
causative urate crystals have a tendency 
for site-speciﬁ  c deposition in the 
joints, which may only periodically 
lead to inﬂ  ammation, despite the 
continuous presence of crystals [17]. 
At a molecular level, attacks of gout 
are associated with activation of the IL-
1β signalling cascade, via the NALP3 
inﬂ  ammasone, in a manner similar to 
some of the HPFs [18,19]. 
    Clinical Studies That Helped Deﬁ  ne 
Autoinﬂ  ammatory Diseases
    Crohn disease is closely 
associated with the seronegative 
spondyloarthropathies, which include 
ankylosing spondylitis, reactive arthritis, 
and psoriatic arthritis. Indeed, most 
patients with ankylosing spondylitis 
have subclinical Crohn disease. Of 
course some of these disorders show 
striking human leukocyte antigen 
  (HLA)-B27   MHC associations, unlike 
Crohn disease, and immune reactivity 
against self has long been suspected as 
an underlying immunopathogenetic 
mechanism [20]. However, recent 
magnetic resonance imaging studies 
have shown that early disease 
localisation in ankylosing spondylitis, 
reactive arthritis, and psoriatic arthritis 
is maximal at, and adjacent to, sites of 
relatively high shear and tensile forces 
      Group A: Canonical cytokine pathway 
blockade for autoinﬂ  ammatory 
disease
   •  TRAPS:  etanercept
  •  Cryopyrinopathies  (chronic  infantile 
neurologic, cutaneous and articular 
syndrome, neonatal onset multisystem 
inﬂ  ammatory disease, Muckle-Wells 
syndrome): anakinra
    •  Gout and FMF: colchicine, which may 
interfere with inﬂ  ammasome activation, 
as well as interference with leukocyte 
motility
    •  Crohn disease: anti-TNF with inﬂ  iximab 
or adalimumab
    •  Ankylosing spondylitis and psoriatic 
arthritis: responsive to all anti-TNF 
therapies
    In Group A, anti-TNF (etanercept) or IL-1β 
blockade with anakinra may be virtually 
curative in some cases of monogenic 
autoinﬂ  ammatory diseases. Colchicine is 
especially effective in FMF and gout, but 
not in autoimmunity. Anti-TNF therapy 
has revolutionised the management 
of Crohn disease and ankylosing 
spondylitis, but conversely, this same 
anticytokine therapy may aggravate 
some autoimmune diseases, including 
systemic lupus erythematosus (SLE) and 
Sjogren syndrome; however, targeting 
of lymphocytes in such autoimmune 
diseases may be effective (see Group 
B). TNF may aggravate autoimmune 
conditions such as SLE in Group B. 
      Group B: Blockade of B and T 
lymphocytes for autoimmunity
   •  SLE:  mycophenolate  moeﬁ  til, 
azathioprine
  •  SLE:  rituximab
  •  Sjogren  syndrome:  rituximab
      Group C: Blockade of cytokines or 
adaptive immune responses
      •  RA: anti-TNF therapy and rituximab 
(anti-B cell)
    •  Psoriasis: anti-TNF therapy and 
efalizumab or alefacept, both of which 
are thought to act primarily by blocking 
T cell migration and activation. 
    In Group C, there is considerable 
heterogeneity in the extent of response 
to biological therapies in diseases such as 
RA and psoriasis. In these two conditions, 
both anticytokine and antilymphocyte 
strategies may be effective, which 
is in keeping with a signiﬁ  cant 
interplay between autoimmune and 
autoinﬂ  ammatory components, as 
proposed in Figure 1. Future therapy 
development and an improved 
understanding of the basis for drug 
resistance in immunological diseases will 
be enhanced by considering the relative 
role of adaptive immunity and innate 
immune factors at target sites of disease. 
  Box 2. The Autoinﬂ  ammatory–Autoimmune Continuum 
and Targeted Therapy in the Immunological Diseases
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at tendon and ligament insertions 
[21]. Bone inﬂ  ammation adjacent to 
insertions may be seen in all of these 
conditions [22]. However, when bone 
inﬂ  ammation is extensive, it is often 
associated with carriage of the   HLA-
B27   gene, suggesting that local factors 
determine the degree of activation 
of the adaptive immune response at 
certain predisposed sites [23]. 
    Collectively, Crohn disease and 
the seronegative arthropathies are 
associated with acneform lesions, 
skin pustulosis, and occasionally 
multifocal osteitis. All of these clinical 
features are variably shared with 
two recently identiﬁ  ed monogenic 
autoinﬂ  ammatory conditions: 
(1) pyogenic arthritis, pyoderma 
gangrenosum, and severe cystic 
acne (PAPA) syndrome and (2) a 
type of chronic multifocal recurrent 
osteomyelitis (CMRO) [24,25]. The 
molecular basis of these monogenic 
equivalents of more common polygenic 
clinical counterparts relates to 
mutations in proteins associated with 
innate immune cell functioning rather 
than with adaptive immunity. This 
suggests that tissue-speciﬁ  c factors in 
the bones, joints, or skin may lead to 
clinical disease expression at certain 
sites (Table 1). 
    In common with ankylosing 
spondylitis and psoriatic arthropathy, 
Behçet disease also has MHC class I 
associations. However, in contrast to 
ankylosing spondylitis and psoriatic 
arthropathy, Behçet disease has 
clinical features that seem to be mostly 
autoinﬂ  ammatory in nature (Table 
S1). Furthermore, particular variants 
of both the FMF gene   (MEFV)   and 
  TNFRSF1A   are more common in 
people with Behçet disease. There 
appears to be overlap between Behçet 
disease, inﬂ  ammatory bowel disease, 
and   MEFV   mutations in general, and 
Ahmet Gül has postulated that poorly 
deﬁ  ned tissue-speciﬁ  c factors in Behçet 
disease may eventually lead to the 
development of secondary autoimmune 
responses [26]. 
    In the case of autoimmune diseases 
such as rheumatoid arthritis (RA), 
studies by Ai Lyn Tan and colleagues 
[27] and by Laura Rhodes and 
colleagues [28] showed that the 
degree of joint inﬂ  ammation, joint 
erosions, and therapeutic responses 
are variably affected by tissue-speciﬁ  c 
factors, including the position of 
joint ligaments. For instance, RA 
erosive changes are more pronounced 
adjacent to the site of maximal stress, 
as exempliﬁ  ed in the index ﬁ  nger 
compared with the ring ﬁ  nger of the 
dominant hand [27]. These studies 
show how secondary autoinﬂ  ammatory 
mechanisms contribute to the clinical 
expression of RA. Based on magnetic 
resonance imaging observations in 
inﬂ  ammatory arthritis, McGonagle and 
colleagues proposed a classiﬁ  cation 
whereby RA is viewed as the archetypal 
autoimmune-mediated synovitis, and 
the seronegative arthropathies are 
considered from the perspective of 
tissue-speciﬁ  c factors related to joint 
insertions [29]. The implications of 
this dichotomous classiﬁ  cation of 
joint disease can be extended to all 
immunological diseases. 
  Implications  for  Autoimmunity
    The autoimmunity paradigm has 
dominated immunology for so long 
that our concepts of many disorders, 
including Crohn disease, have been 
moulded to ﬁ  t the prevailing dogma. 
Placing immunological disease along 
this proposed continuum allows the 
relative contribution of different types 
of self-directed inﬂ  ammation to be 
considered without assuming that an 
adaptive immune response is central to 
disease pathogenesis. 
    The case of vasculitis (blood 
vessel inﬂ  ammation) illustrates the 
usefulness of a continuum view 
of immunological disease. The 
autoimmune-mediated vasculitides 
can be distinguished clinically 
by the presence of pathogenic 
autoantibodies, including 
DOI: 10.1371/journal.pmed.0030297.g001
  Figure 1.   The Immunological Disease Continuum, with Examples   
  The  monogenic  “autoinﬂ  ammatory” diseases may be exclusively determined by local tissue-
speciﬁ  c factors. For rare monogenic “autoimmune” conditions, the disease localisation appears 
to be determined predominantly by the adaptive immune response. The clinical heterogeneity 
within the immunological diseases, both among patients and between populations, may reﬂ  ect 
the variable expression of autoinﬂ  ammatory and autoimmune factors in disease causation. For 
example, in humans, there is considerable genetic and molecular evidence for uveitis falling into 
all of the disease categories, with the exception of the rare monogenic autoimmune diseases. 
There is also considerable overlap between polygenic autoinﬂ  ammatory diseases and MHC class 
1–associated diseases, but to simplify classiﬁ  cation, these are split up into different categories. This 
ﬁ  gure does not include all immunologically recognised diseases because of their large number.  
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antineutrophil cytoplasmic antibodies 
(ANCA). It is of note, therefore, 
that the nonautoantibody-associated 
vasculitides, including Takayasu 
arteritis and giant cell arteritis, affect 
particular vascular territories in a 
patchy manner, thereby illustrating 
the contribution of local factors to 
disease pathogenesis (Table S1). 
Thus far, evidence for tissue-speciﬁ  c 
factors inﬂ  uencing the expression 
of autoimmune diseases in humans, 
such as type 1 diabetes, is lacking, 
but the concept of secondary 
autoinﬂ  ammation in autoimmunity 
offers an alternative perspective on 
how genetic or environmental factors 
affecting disease-prone sites could lead 
to, or alter, clinical disease expression. 
    The classiﬁ  cation of MHC class 
I–associated diseases as autoimmune 
has been contentious given that these 
conditions lack speciﬁ  c autoantibody 
associations. The present classiﬁ  cation 
places   HLA-B27  -related conditions and 
other MHC class I–associated diseases 
as intermediates—or “at a half-way 
house”—between autoinﬂ  ammation 
and autoimmunity. As outlined earlier, 
tissue-speciﬁ  c factors at disease-prone 
sites appear to be instrumental in 
localisation of these conditions. While 
this article deals exclusively with self-
directed tissue inﬂ  ammation, immune-
reactivity reactions against nonself 
(such as reactions to organ transplants) 
help illustrate the concept of MHC 
class I–associated diseases being “half-
way houses.” In the transplantation 
ﬁ  eld, renal rejection reactions are 
strongly associated with MHC class 
I antigens and with tissue-speciﬁ  c 
factors, especially the duration of organ 
ischemia. In fact, if organ ischemia is 
minimised, then MHC-mismatched 
grafts survive as well as matched grafts, 
thus showing how adaptive immunity 
and local tissue factors interact in 
disease expression [30] in the context 
of MHC class I associations.
    In certain clinically deﬁ  ned 
autoimmune scenarios, including 
RA, it appears that some patients 
do in fact have a disease that is 
predominately autoinﬂ  ammatory in 
nature. In a study of patients with 
benign polyarthritis of the elderly, 
which often meets diagnostic criteria 
for RA and has a good prognosis but 
lacks the autoantibody association, 
McGonagle and colleagues observed 
that the pattern of disease localisation 
was similar to the seronegative 
arthropathies. In other words, 
joint disease tended to involve the 
periarticular structures rather than the 
synovium [31]. The good prognosis 
in benign polyarthritis is similar to 
reactive arthritis, which is a type 
of seronegative arthritis. Thus, the 
variable prognosis in diseases such 
as RA and multiple sclerosis may be 
related to the predominance of either 
autoinﬂ  ammation or autoimmunity, 
with the former generally equating to a 
better prognosis. 
    The formal recognition of 
autoinﬂ  ammation also has implications 
for a better clinical understanding 
of the targeted therapy of the 
immunological diseases. For example, 
anticytokine therapy is especially 
effective in autoinﬂ  ammatory disease; 
the interleukin-1 receptor antagonist 
anakinra shows good efﬁ  cacy in 
some monogenic autoinﬂ  ammatory 
disorders [32]. On the other hand, 
strategies to target lymphocytes are 
especially effective in autoimmune 
diseases, such as lupus. In some cases, 
both anticytokine and antilymphocyte 
strategies are effective in disorders that 
lie somewhere along the autoimmune–
autoinﬂ  ammatory disease continuum 
    Landmark Papers That Set the Scene 
for Proposing an Autoimmune–
Autoinﬂ  ammation Spectrum
    1.  Burnet  et  al.  [1] 
      The seminal work of Burnet and others 
set the scene for understanding the 
nature of autoimmunity. 
      2. McDermott et al. [7] 
      This article showed that some 
inﬂ  ammation directed against self 
was due to mutations in the TNF 
receptor and introduced the concept of 
autoinﬂ  ammation. Since TNF is pivotal 
in innate immune responses, the work 
conﬁ  rmed that this disease process was 
very different from autoimmunity at the 
molecular level. 
      3. Hugot et al. and Ogura Y et al. 
[13,14] 
      Until this work, Crohn disease was 
conceptualised in relationship to 
autoimmune mechanisms. These studies 
were published simultaneously, and 
showed that mutations in a protein 
associated with innate immune 
responses played a key role in a subgroup 
of patients with Crohn disease.
      4. Martinon et al. [18]
      This paper showed that the molecular 
pathways associated with immune 
activation in gout and pseudogout 
were very similar to those associated 
with immune activation in some of the 
monogenic autoinﬂ  ammatory diseases. 
This mechanistic link shows how 
multifactorial common diseases, without 
a clearly deﬁ  ned genetic basis, are linked 
to autoinﬂ  ammation. 
   5.  Matzinger  [34] 
      The author argued that the danger 
theory stood on the shoulders of the 
self/nonself discrimination theory, and 
thus explained autoimmunity. However, 
the danger theory nicely illustrates 
the role of innate immune responses, 
which are independent of self/nonself 
discrimination, as a mechanism for self-
directed tissue inﬂ  ammation.  
DOI: 10.1371/journal.pmed.0030297.g002
  Figure 2.   Recognition of Autoinﬂ  ammation: 
Psoriatic Arthritis as an Example
      In early RA, joint disease localisation is to 
the synovium—in keeping with the concept 
of the synovium being the primary target 
organ. However, in early psoriatic arthritis, 
the inﬂ  ammatory changes have a widespread 
distribution and appear to relate to patterns 
of joint stressing around ligaments, adjacent 
bone, and soft tissues, rather than a speciﬁ  c 
antigen territory. The ﬁ  gure shows a contrast-
enhanced high-resolution magnetic resonance 
image of a distal interphalangeal joint 
optimised for showing sites of inﬂ  ammation 
(pixel size, 100 ×100 microns). There are 
extensive inﬂ  ammatory changes in all tissues. 
    Asterisk, site of diffuse osteitis; arrowhead, 
synovial enhancement; solid arrows, joint 
ligaments that show ﬂ  orid inﬂ  ammatory 
changes at insertions and within ligaments; 
open arrow, extracapsular soft-tissue 
enhancement.  
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(Box 2). Finally, cytokine blockade of 
diseases with a strong autoinﬂ  ammatory 
basis may aggravate or precipitate 
autoimmune diseases such as lupus. 
Placing inﬂ  ammatory disease along 
a continuum, therefore, may have 
relevance for therapy development, 
since disorders with a prominent 
autoinﬂ  ammatory component could 
be targeted via innate immune pathway 
blockade. 
  Reﬁ  ning our Understanding 
of Immunology
    The concept of autoinﬂ  ammation 
has implications for our theoretical 
understanding of immunology. 
The two theories of self-directed 
immunity—the self/nonself 
discrimination theory and the 
danger signal theory—place the 
emphasis on different aspects of how 
autoimmunity develops and argue for 
different theoretical rationales for 
immunological disease. In physics, 
the nature of matter cannot be readily 
understood in terms of either particles 
or waves, so the wave–particle duality 
arose. Likewise, many aspects of 
classically recognised autoimmune 
diseases are best viewed in terms 
of self/nonself discrimination and, 
conversely, the autoinﬂ  ammatory 
diseases are best viewed from the 
perspective of tissue-speciﬁ  c danger 
signals. For example, uric acid—the 
causative molecule in gout—is a 
recognised danger signal [33]. From 
the standpoint of the danger theory, 
the ultimate susceptibility to disease 
lies not with the adaptive immune 
system but with the target tissue itself, 
from which danger signals emanate 
[34]; this hypothesis is closely allied 
with the proposed generic deﬁ  nition 
of autoinﬂ  ammation. Looking at 
immunological disease from the 
autoimmunity perspective, several 
groups have drawn attention to the 
possible role of tissue-speciﬁ  c factors 
in autoimmunity [35]. 
    A better clinical understanding 
of diseases may be achieved by 
purposely looking for speciﬁ  c 
autoinﬂ  ammatory and autoimmune 
features. For example, the idea of 
coeliac disease being autoimmune 
in nature is questionable given the 
exogenous nature of the causative 
gluten antigen. However, when 
viewed from the perspective of 
tissue-speciﬁ  c components, such as 
altered gut permeability following 
inciting infections and gut tissue 
transglutaminase-mediated gluten 
peptide modiﬁ  cation, then a unifying 
basis can be conceptualised [36]. 
Conversely, the idea that Crohn 
disease and ulcerative colitis are 
autoinﬂ  ammatory in nature is also 
questionable given their associations 
with p-antineutrophil cytoplasmic 
autoantibodies [37]. It remains 
to be determined whether the 
autoantibody association represents 
secondary autoimmunity or disease 
heterogeneity, with some cases being 
predominantly autoimmune and others 
autoinﬂ  ammatory. 
  Conclusions
    The formal recognition and genetic 
understanding of the autoinﬂ  ammatory 
diseases has deﬁ  ned mechanisms 
of self-directed inﬂ  ammation 
that are independent of adaptive 
immunity. If we adopt a “continuum 
model” of immunology, in which 
diseases lie on a spectrum from 
autoimmune to autoinﬂ  ammatory, 
we can begin to deﬁ  ne the 
relative contributions of both the 
innate and the adaptive immune 
responses to particular diseases. All 
noninfectious inﬂ  ammatory disease 
can be accommodated within this 
classiﬁ  cation. 
    Animal models of autoimmune 
disease have been very instructive 
for elucidating molecular pathways 
of many conditions. However, in 
order to adequately assess the role 
of individual tissue-speciﬁ  c factors, 
studies will need to focus on the role 
of site-speciﬁ  c factors in humans. 
Future clinical studies are needed to 
develop imaging strategies, including 
molecular imaging, as well as to 
determine the basis for inﬂ  ammation 
at certain predisposed sites (Figure 
2). Studies of tissues that are subject 
to autoinﬂ  ammatory reactions in 
diseases such as multiple sclerosis 
need to explore autoinﬂ  ammatory 
mechanisms in disease expression 
that have been neglected to date. 
The autoinﬂ  ammatory–autoimmune 
continuum offers an inclusive 
classiﬁ  cation of immunological disease 
and a better understanding of the 
pathogenesis and treatment of self-
directed inﬂ  ammation.  
  Supporting  Information
      Table S1.   Clinical Aspects of Pure 
Autoinﬂ  ammation versus Pure 
Autoimmunity
  Table 2.   Immunological Aspects of Pure Autoinﬂ  ammation versus Pure Autoimmunity    
Variable Autoinﬂ  ammatory Autoimmune
Factors determining disease 
manifestations
Local tissue factors at disease-prone sites, including tissue trauma, 
necrosis, mechanical factors, and bacteria or their constituent 
molecules
Clinical disease expression determined by events taking place in 
primary and secondary lymphoid tissues, including bone marrow, 
thymus, lymph nodes, and spleen
Innate immune activation Adaptive immune activation
Key theory relating to disease 
expression
The danger signal theory of Matzinger, with tissue-speciﬁ  c factors 
determining disease localisation
The major factor determining disease is aberrant SNS discrimination, 
with breakdown of immunological tolerance
Immunological basis Genetically related to perturbations of innate immune function, 
including pro-inﬂ  ammatory cytokine signalling abnormalities/
bacterial sensing/local tissue abnormalities
Acquired immune perturbation key-to-disease expression
Cellular basis Expression determined by cells of innate immune system, including 
neutrophils and macrophages or nonimmune cells
Expression mainly determined by factors affecting B and T cell 
activity
Genetic mutations in HPFs, including TRAPS and FMF, affect these 
cells
Genetic mutations in rare autoimmune diseases affect these cells or 
their selection in thymus
 DOI:  10.1371/journal.pmed.0030297.t002
    This table represents some of the key features that allow differentiation of a “pure autoinﬂ  ammatory disease” from a “pure autoimmune disease.” The rare monogenic HPFs are the 
prototypic autoinﬂ  ammatory diseases, whereas the prototypes for autoimmune diseases include the polygenic MHC and autoantibody-related diseases, as well as some rare monogenic 
diseases. SNS, self/nonself. 
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    This table represents key features that allow 
differentiation of a “pure autoinﬂ  ammatory 
disease” from a “pure autoimmune 
disease” in the clinical setting. As outlined 
in the text, there is increasing evidence 
for an interaction between autoimmune 
and autoinﬂ  ammatory mechanisms in 
the phenotypic expression of common 
polygenic diseases, where overlapping 
features may be evident. 
    DOI: 10.1371/journal.pmed.0030297.st001 
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in Immune Disease Localisation
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